Power Law company profile

Nuvalent

Biotech & Life Sciences · Cambridge, United States · Founded 2017 · IPO 2021 Unicorn

Creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets

Valuation

$6.54B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

12 investors on Nuvalent's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Deerfield

Series B+ 11 investors entered at this stage

Boxer Capital

Wellington Management

Fidelity Investments

Driehaus Capital Management

Logos Capital

Venrock

Janus Henderson Investors

Avoro Capital Advisors

Viking Global Investors

Fairmount Funds Management

Bain Capital Life Sciences

Global footprint

Where Nuvalent has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Web traffic by country

28K monthly visits
across markets

🇺🇸 United States91.8%

🇨🇦 Canada4.3%

🇮🇳 India3.6%

Top 3 markets shown

Market sentiment

What the market is saying about Nuvalent

An AI-synthesized read of the highest-engagement posts about Nuvalent on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nuvalent on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles